Question: Example(question='There has been an outbreak of an viral infectious disease in your city. You have been asked to design a molecular diagnostic kit for quick detection of this retrovirus. How would you go about designing this kit?', choice1='First you identify the virus by performing DNA sequencing. You then develop a PCR kit for  quick and accurate diagnosis', choice2='First you identify the IgG antibodies for the infection. You then develop an ELISA kit targeting IgG antibodies for quick \n and accurate diagnosis.', choice3='First you identify the virus using the information about the symptoms, provided by the affected patients. You then design a nested PCR kit based on the information for quick diagnosis.', choice4='First you identify the virus by performing cDNA sequencing.  You then develop a real time PCR kit for quick and accurate diagnosis.', correct_index=3)
Iteration: abstracted_workflow_2_156
proposed answer: The validation cannot be fully evaluated without actual numerical data. We need measured sensitivity, specificity with confidence intervals, LOD and timing metrics to assess whether the kit meets predefined criteria.

Answer:1. Assemble sample panels:
   • Positive clinical samples confirmed by gold-standard method
   • Negative controls and cross-reactivity panel
2. Analytical sensitivity (LOD):
   • Test serial dilutions (10^5–1 copies/reaction) in ≥20 replicates
   • Determine lowest concentration detected in ≥95% of replicates
3. Analytical specificity:
   • Test cross-reactivity panel in triplicate
   • Confirm no false positives
4. Clinical performance:
   • Test ≥100 known positives and ≥100 known negatives
   • Calculate sensitivity and specificity with 95% CIs
5. Rapidity:
   • Record hands-on and total run times (goal ≤2 h)
6. Reproducibility and robustness:
   • Assess inter- and intra-run precision (Ct variation ≤1)
7. Data analysis & acceptance:
   • Sensitivity ≥95%, specificity ≥98%, LOD ≤10 copies, turnaround ≤2 h
8. Documentation & regulatory submission
[TOO_HARD]
Please provide measured sensitivity and specificity values (with 95% CIs), determined LOD results, and recorded hands-on plus total run times for detailed critical evaluation.
Extracted answer: 1. Assemble sample panels:
Correct answer: 3
Question: Example(question='There has been an outbreak of an viral infectious disease in your city. You have been asked to design a molecular diagnostic kit for quick detection of this retrovirus. How would you go about designing this kit?', choice1='First you identify the virus by performing DNA sequencing. You then develop a PCR kit for  quick and accurate diagnosis', choice2='First you identify the IgG antibodies for the infection. You then develop an ELISA kit targeting IgG antibodies for quick \n and accurate diagnosis.', choice3='First you identify the virus using the information about the symptoms, provided by the affected patients. You then design a nested PCR kit based on the information for quick diagnosis.', choice4='First you identify the virus by performing cDNA sequencing.  You then develop a real time PCR kit for quick and accurate diagnosis.', correct_index=3)
Iteration: abstracted_workflow_16_156
proposed answer: The validation workflow needs to cover clinical study design, sample diversity, statistical power, comparator methods, cross-reactivity, and multicenter assessment, but key details (sample panel composition, prevalence, gold standard, specimen types) are missing. I will provide a comprehensive protocol and flag missing information as [TOO_HARD] with a request for specifics.

Answer:1. Study design and ethical approval:
   • Obtain IRB approval and informed consent.
   • Define target sample size using expected prevalence, desired sensitivity/specificity, and statistical power calculations.
   • Ensure diversity in age, disease severity, geographic location, and co-infection status.
2. Reference standard and sample classification:
   • Use a well-established gold-standard comparator (e.g., viral culture or reference RT-PCR assay).
   • Collect multiple specimen types (e.g., blood, respiratory swabs, saliva) in validated transport media.
   • Characterize each sample as true positive or negative by the comparator.
3. Blinded, randomized testing:
   • Label samples with unique codes and blind operators to status.
   • Run the new RT-PCR kit with internal controls (positive, negative, no-template) in each batch.
4. Data collection and analysis:
   • Record Ct values and qualitative calls for all specimens and controls.
   • Calculate sensitivity, specificity, PPV, NPV with 95% confidence intervals.
   • Construct ROC curve; compute AUC.
   • Assess reproducibility: intra- and inter-run precision (CV of Ct values).
5. Cross-reactivity and specificity panel:
   • Test against related viruses (other retroviruses, common respiratory pathogens).
   • Evaluate impact of potential interfering substances.
6. Multicenter and matrix validation:
   • Perform external validation at ≥2 independent laboratories.
   • Test additional specimen types and collection methods.
7. Clinical concordance and statistical measures:
   • Compute Cohen’s kappa between new kit and reference method.
   • Analyze discrepant results and perform sequencing or alternative testing for resolution.
8. Reporting:
   • Summarize LOD, dynamic range, sensitivity/specificity, PPV/NPV, AUC, reproducibility, and cross-reactivity findings.
   • Document limitations, sample stability, and user instructions.
[TOO_HARD]
Please provide: (a) detailed panel of well-characterized clinical samples (with age, severity, co-infections), (b) prevalence estimates and sample size/statistical power calculations, (c) chosen gold-standard comparator assay, and (d) list of specimen types and transport media to finalize validation protocols.
Extracted answer: 1. Study design and ethical approval:
Correct answer: 3
